

119TH CONGRESS  
1ST SESSION

# S. 2336

To ensure references to opioid overdose reversal agents in certain grant programs of the Department of Health and Human Services are not limited to naloxone.

---

## IN THE SENATE OF THE UNITED STATES

JULY 17, 2025

Mr. CORNYN (for himself and Ms. HASSAN) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions

---

## A BILL

To ensure references to opioid overdose reversal agents in certain grant programs of the Department of Health and Human Services are not limited to naloxone.

1 *Be it enacted by the Senate and House of Representa-*  
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Halting the Epidemic  
5 of Addiction and Loss Act of 2025”.

6 **SEC. 2. REFERENCES TO OPIOID OVERDOSE REVERSAL**  
7 **AGENTS IN HHS GRANT PROGRAMS.**

8 (a) IN GENERAL.—The Secretary of Health and  
9 Human Services shall ensure that, as appropriate, when-

1 ever the Department of Health and Human Services  
2 issues a regulation or guidance for any grant program ad-  
3 dressing opioid misuse and use disorders, any reference  
4 to an opioid overdose reversal drug (such as a reference  
5 to naloxone) is inclusive of any opioid overdose reversal  
6 drug that has been approved under section 505 of the Fed-  
7 eral Food, Drug, and Cosmetic Act (21 U.S.C. 355) for  
8 emergency treatment of a known or suspected opioid over-  
9 dose.

10 (b) EXISTING REFERENCES.—

11 (1) UPDATE.—Not later than one year after the  
12 date of enactment of this Act, the Secretary of  
13 Health and Human Services shall update all ref-  
14 erences described in paragraph (2) to be inclusive of  
15 any opioid overdose reversal drug that has been ap-  
16 proved or otherwise authorized for use by the Food  
17 and Drug Administration.

18 (2) REFERENCES.—A reference described in  
19 this paragraph is any reference to an opioid overdose  
20 reversal drug (such as naloxone) in any regulation or  
21 guidance of the Department of Health and Human  
22 Services that—

23 (A) was issued before the date of enact-  
24 ment of this Act; and

25 (B) is included in—

1 (i) the grant program for State and  
2 Tribal response to opioid use disorders  
3 under section 1003 of the 21st Century  
4 Cures Act (42 U.S.C. 290ee–3a) (com-  
5 monly referred to as “State Opioid Re-  
6 sponse Grants” and “Tribal Opioid Re-  
7 sponse Grants”); or

8 (ii) the grant program for priority  
9 substance use disorder prevention needs of  
10 regional and national significance under  
11 section 516 of the Public Health Service  
12 Act (42 U.S.C. 290bb–22).

○